T0	Participants 102 222	patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both.
T1	Participants 577 707	patients with systolic dysfunction and heart failure receiving therapeutic inhibition of the renin-angiotensin-aldosterone system.
T2	Participants 888 948	768 treated patients with heart failure measured at baseline
T3	Participants 1926 1961	treated patients with heart failure